GleamWall
中文EN

NERV Minerva Neurosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1598646 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,973.5%
TTM EPS YoY-1,728.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-460.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets187.3%
Debt / equity—
Current ratio33.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-410.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$5.76M$11.90M
SG&A expense$9.34M$9.95M
Operating income-$15.10M-$21.85M
Net income-$293.42M$1.44M
EBITDA-$15.10M-$21.84M
EPS (basic)-34.670.19
EPS (diluted)-34.670.19
Weighted avg. shares (diluted)8.46M7.57M
Balance sheet
Cash & equivalents$82.30M$21.36M
Current assets$83.10M$22.27M
PP&E, net$0$5,442
Goodwill$14.87M$14.87M
Total assets$97.97M$37.14M
Current liabilities$2.29M$2.84M
Total liabilities$233.76M$62.84M
Shareholders' equity-$140.75M-$25.69M
Shares outstanding43.27M6.99M
Cash flow statement
Operating cash flow-$13.51M-$19.55M
Investing cash flow$0$0
Financing cash flow$74.45M—
Depreciation & amortization$5,442$5,442
Stock-based compensation$1.33M$1.33M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.